Fallypride

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Fallypride
DrugBank Accession Number
DB15167
Background

Fallypride is under investigation in clinical trial NCT02310360 (Striatal and Extra-striatal Dopamine Release in Response to Food in Healthy Humans).

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 364.461
Monoisotopic: 364.216220965
Chemical Formula
C20H29FN2O3
Synonyms
Not Available

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
ApomorphineThe therapeutic efficacy of Apomorphine can be decreased when used in combination with Fallypride.
AripiprazoleThe therapeutic efficacy of Aripiprazole can be decreased when used in combination with Fallypride.
BenzatropineThe risk or severity of adverse effects can be increased when Fallypride is combined with Benzatropine.
BrexpiprazoleThe therapeutic efficacy of Brexpiprazole can be decreased when used in combination with Fallypride.
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Fallypride.
CabergolineThe therapeutic efficacy of Cabergoline can be decreased when used in combination with Fallypride.
DeutetrabenazineThe risk or severity of adverse effects can be increased when Fallypride is combined with Deutetrabenazine.
DihydroergocornineThe therapeutic efficacy of Dihydroergocornine can be decreased when used in combination with Fallypride.
DihydroergotamineThe therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Fallypride.
DopexamineThe therapeutic efficacy of Dopexamine can be decreased when used in combination with Fallypride.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
G9FWZ369GX
CAS number
166173-78-0
InChI Key
OABRYNHZQBZDMG-INIZCTEOSA-N
InChI
InChI=1S/C20H29FN2O3/c1-4-10-23-11-6-8-16(23)14-22-20(24)17-12-15(7-5-9-21)13-18(25-2)19(17)26-3/h4,12-13,16H,1,5-11,14H2,2-3H3,(H,22,24)/t16-/m0/s1
IUPAC Name
5-(3-fluoropropyl)-2,3-dimethoxy-N-{[(2S)-1-(prop-2-en-1-yl)pyrrolidin-2-yl]methyl}benzamide
SMILES
COC1=C(OC)C(=CC(CCCF)=C1)C(=O)NC[C@@H]1CCCN1CC=C

References

General References
Not Available
ChemSpider
8197265
BindingDB
50220541
ChEMBL
CHEMBL392158
ZINC
ZINC000006483622
Wikipedia
Fallypride

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentHealthy Volunteers1
1CompletedBasic ScienceObesity, Morbid1
Not AvailableCompletedNot AvailableType1 Diabetes Mellitus1
Not AvailableRecruitingBasic ScienceBMI >27 kg/m2 / BMI >30 kg/m2 / Healthy Volunteers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0419 mg/mLALOGPS
logP2.76ALOGPS
logP2.8ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)13.84ChemAxon
pKa (Strongest Basic)7.93ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area50.8 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity101.83 m3·mol-1ChemAxon
Polarizability40.09 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on May 20, 2019 14:55 / Updated on June 12, 2020 16:53